Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment

* Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 50 years * Subfoveal FVPED assessed using clinical examination and OCT * Best corrected visual acuity in the study eye between 20 and 85 letters on the ETDRS chart (20/30 to 20/800 Snellen equivalent) * Prior treatment with at least 6 consecutive injections with ranibizumab 0.5 mg prior to the baseline visit; the last treatment with ranibizumab should not exceed 45 days from the baseline visit. Exclusion Criteria: * Pregnancy (positive pregnancy test) or lactation * Participation in another simultaneous medical investigation or trial * Prior treatment with ranibizumab therapy in the study eye within 30 days of baseline * Prior treatment with PDT in the study eye * Prior intravitreal injection of a corticosteroid (triamcinolone, dexamethasone) within 120 days from baseline. * Presence of significant subfoveal fibrosis or atrophy determined using SDOCT, fluorescein angiography and clinical examination. * Presence of fibrous or fibrocellular material occupying more than 50% of the sub-RPE space; assessed using EDI OCT * Presence of a RPE tear, determined by clinical examination, FA, FAF and OCT * Intraocular surgery (including cataract surgery) in the study eye within 90 days preceding baseline * History of pars plana vitrectomy, submacular surgery or any other surgical intervention for vitreo-retinal diseases in the study eye * Presence of or previous hi…